Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Derrick J. Rose, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA
Moderna will deliver 7.5 million doses of COVID-19 vaccine to Switzerland in batches in the months ahead, putting the country among the world leaders in inoculating its population, the head of Moderna's European business said. Staner said Switzerland would not get privileged treatment because it was the first country to chose Moderna as a supplier. Swiss regulators have approved vaccines from Moderna and from Pfizer with partner BioNTech.